Gastroparesis Treatments

Find Gastroparesis Treatments

Generic Name

Metoclopramide

Brand Names

Reglan, Gimoti

FDA approval date: September 30, 1990

Classification: Dopamine-2 Receptor Antagonist

Form: Injection, Spray, Tablet, Solution

What is Reglan (Metoclopramide)?

Diabetic Gastroparesis Metoclopramide Injection, USP is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The Prevention of Nausea and Vomiting Associated with Emetogenic Cancer Chemotherapy Metoclopramide Injection, USP is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy. The Prevention of Postoperative Nausea and Vomiting Metoclopramide Injection, USP is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable. Small Bowel Intubation Metoclopramide Injection, USP may be used to facilitate small bowel intubation in adults and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers. Radiological Examination Metoclopramide Injection, USP may be used to stimulate gastric emptying and intestinal transit of barium in cases where delayed emptying interferes with radiological examination of the stomach and/or small intestine.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Restoration of Hypoglycemia Awareness With Metoclopramide

Who is this study for: Adult patients with type 1 diabetes

Enrollment Status: Recruiting

Publish Date: March 20, 2026

Intervention Type: Drug

Study Drug: Metoclopramide

Study Phase: Phase 2

Summary: Metoclopramide is a drug approved by the FDA for gastroesophageal reflux and to relieve symptoms in adults with acute and recurrent diabetic gastroparesis. The objective of this study is to determine whether metoclopramide can improve hypoglycemia awareness and decrease the incidence of hypoglycemia in type 1 diabetes patients with hypoglycemia unawareness.

Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting

Enrollment Status: Recruiting

Publish Date: March 04, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: The goal of this clinical trial is to evaluate the efficacy and safety of olanzapine plus metoclopramide in preventing opioid-induced nausea and vomiting (OINV) in adult patients with advanced cancer who are initiating strong opioid therapy. The main questions it aims to answer are: (1) Does the combination of olanzapine and metoclopramide reduce the incidence of OINV? (2)What adverse events do pa...

A Human Experimental Medicine Study to Assess Whether the Gut Microbiota Regulates Specific and Non-specific Immune Responses to Vaccination

Enrollment Status: Recruiting

Publish Date: December 10, 2025

Intervention Type: Drug, Biological

Study Phase: Phase 4

Summary: The goal of this clinical trial is to examine immune responses to the BCG vaccine in healthy adults who have, or who have not, taken antibiotics to deplete their gut bacteria prior to vaccination. The main question it aims to answer is: does depletion of the gut microbiota lead to impaired BCG-induced protection against specific and non-specific to challenges to the immune system?

View All Clinical Trials